Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells ... T-cell products target surface proteins found on normal B-cells and B-cell-derived cancers. Data from clinical trials ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

A study shares new insights into how two of the most common types of chimeric antigen receptor (CAR ... that maximize antitumor activity beyond B cell malignancies. "We looked at two different ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...